Research Library › Articles · View in catalog →
BAM15
Also indexed as BAM 15, BAM-15, N6-bis(2-fluorophenyl)-[1,2,5]oxadiazolo[3,4-b]pyrazine-5, 6-diamine
1 Identity
Non-peptide small molecules. and by the systematic name N5. CAS 210302-17-3. A second number, CAS 5306-85-4, circulates in parts of the channel and does not index to this structure.
- Sequence
- No sequence. This is not a peptide: no residues, no termini, no counterion in the peptide sense, no net peptide content. The article is the fused heterocycle N5,N6-bis(2-fluorophenyl)-[1,2,5]oxadiazolo[3,4-b]pyrazine-5,6-diamine — a furazano-fused pyrazine bearing two arylamino substituents, each aryl group a 2-fluorophenyl. Achiral: no stereocenter, so no chiral method applies and none should appear on the certificate. Supplied as a neutral crystalline solid, not as a salt. Because it is not a peptide, it cannot inherit a peptide panel.
- Molecular formula
- C16H10F2N6O
- Average mass
- 340.2938 Da (C16H10F2N6O) on IUPAC 2021 conventional atomic weights. Listings commonly print 340.29; the formula gives 340.2938.
- Monoisotopic mass
- 340.0884 Da neutral. Working ions: [M+H]+ m/z 341.0957, [M-H]- m/z 339.0811. Two fluorines and six nitrogens give this molecule a distinctive isotope pattern, and the M+1 relative intensity is itself an identity check.
- Salt / variant note
- (1) the peptide name collision is the first-order risk and it is a naming risk, not a chemistry risk: BAM8-22 (C121H188N32O30S, a 15-residue bovine adrenal medulla peptide) and BAM12P are peptides with entirely unrelated structures and masses, and a purchasing error between "BAM15" and "BAM 8-22" cannot be caught by anything on a peptide release panel. (2) the des-fluoro and mono-fluoro analogues: the unsubstituted N5,N6-diphenyl parent is C16H12N6O, 304.31 avg / 304.1073 mono, -36.0 Da (two F replaced by two H); the mono-fluoro species C16H11FN6O is 322.30 avg / 322.0978 mono, -18.0 Da. Both are plausible synthesis-related species and both are resolvable arithmetically. (3) positional isomers of the fluorine — 3-fluorophenyl and 4-fluorophenyl analogues are identical in formula and identical in exact mass to every decimal place, so mass spectrometry cannot separate them at any resolution and 19F and 1H NMR are the only methods that can. This is the mass-silent variant on this molecule and it is the reason NMR is mandatory rather than optional; no default panel in the catalog carries 19F NMR, so it has to be specified for this article and never assumed. (4) N-OXIDES and the ring-opened furazan products, +15.995 Da and related, as oxidative degradants. (5) Consumer-channel capsule presentations, typically 15 mg per capsule, in which the article of commerce is a formulation and no purity figure on the neat compound is recoverable at all; the compound also circulates as a component of an oral blend with SLU-PP-332, where it is named but never identified.
2 Class & testing panel
- Form
- Single article
- Testing panel
- P6 — panel definition
3 Primary sources & evidence
Preclinical only. The compound's characterization in the peer-reviewed literature begins with Kenwood BM et al., Molecular Metabolism 2014;3:114-123 (PMID 24944896), an in-vitro and isolated-mitochondria study, followed by a rodent literature in metabolic-research journals from 2014 onward. No ClinicalTrials.gov registration under BAM15 or CAS 210302-17-3 was identified; no controlled human trial was identified; no marketing authorization exists in any jurisdiction; and no pharmacopeial monograph exists.
4 Storage & specification
- Storage
- Crystalline solid, 2 to 8 degrees C or -20 degrees C plus or minus 5 degrees C, desiccated, protected from light, container closed under an inert headspace. The nitroaromatic-type chromophore makes photoprotection a specification item; the furazan ring is the feature to watch on oxidative and thermal stress.
- Shelf life
- The retest interval is 36 months at 2 to 8 degrees C for a small-molecule crystalline solid, assigned by protocol. The stability protocol is an ICH Q1A three-lot study with an ICH Q1B photostability arm, with the N-oxide and any ring-opened furazan product as the indicating impurities.
This record reports identity, specification and study design. It does not state what the article does in a human body. Supplied under the caution: “CAUTION: Contains a new drug for investigational use only in laboratory research animals or for tests in vitro. Not for use in humans.”
